Literature DB >> 21969934

Normal expiratory flow rate and lung volumes in patients with combined emphysema and interstitial lung disease: a case series and literature review.

Karen L Heathcote1, Donald W Cockcroft, Derek A Fladeland, Mark E Fenton.   

Abstract

Pulmonary function tests in patients with idiopathic pulmonary fibrosis characteristically show a restrictive pattern including small lung volumes and increased expiratory flow rates resulting from a reduction in pulmonary compliance due to diffuse fibrosis. Conversely, an obstructive pattern with hyperinflation results in emphysema by loss of elastic recoil, expiratory collapse of the peripheral airways and air trapping. When the diseases coexist, pulmonary volumes are compensated, and a smaller than expected reduction or even normal lung volumes can be found. The present report describes 10 patients with progressive breathlessness, three of whom experienced severe limitation in their quality of life. All patients showed lung interstitial involvement and emphysema on computed tomography scan of the chest. The 10 patients showed normal spirometry and lung volumes with severe compromise of gas exchange. Normal lung volumes do not exclude diagnosis of idiopathic pulmonary fibrosis in patients with concomitant emphysema. The relatively preserved lung volumes may underestimate the severity of idiopathic pulmonary fibrosis and attenuate its effects on lung function parameters.

Entities:  

Mesh:

Year:  2011        PMID: 21969934      PMCID: PMC3267611          DOI: 10.1155/2011/354325

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  16 in total

1.  Near normalization of spirometry in a subject with severe emphysema complicated by amiodarone lung.

Authors:  D W Cockcroft; K L Fisher
Journal:  Respir Med       Date:  1999-08       Impact factor: 3.415

2.  Pulmonary mechanics in diffuse fibrosing alveolitis.

Authors:  J C Yernault; M de Jonghe; A de Coster; M Englert
Journal:  Bull Physiopathol Respir (Nancy)       Date:  1975 Mar-Apr

Review 3.  Pathogenesis of chronic obstructive pulmonary disease.

Authors:  William MacNee
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus.

Authors:  H Mori; M Okubo; M Okamura; K Yamane; S Kado; G Egusa; T Hiramoto; H Hara; M Yamakido
Journal:  Intern Med       Date:  1992-02       Impact factor: 1.271

5.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.

Authors:  V Cottin; H Nunes; P-Y Brillet; P Delaval; G Devouassoux; I Tillie-Leblond; D Israel-Biet; I Court-Fortune; D Valeyre; J-F Cordier
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

6.  Pulmonary diffusing capacity in chronic renal failure.

Authors:  J W Forman; L N Ayers; W C Miller
Journal:  Br J Dis Chest       Date:  1981-01

7.  Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment.

Authors:  J Wiggins; B Strickland; M Turner-Warwick
Journal:  Respir Med       Date:  1990-09       Impact factor: 3.415

8.  Reduced diffusing capacity as an isolated finding in asbestos- and silica-exposed workers.

Authors:  J G Garcia; D E Griffith; J S Williams; W J Blevins; R S Kronenberg
Journal:  Chest       Date:  1990-07       Impact factor: 9.410

9.  Clinical characteristics of combined pulmonary fibrosis and emphysema.

Authors:  Yoshiaki Kitaguchi; Keisaku Fujimoto; Masayuki Hanaoka; Satoshi Kawakami; Takayuki Honda; Keishi Kubo
Journal:  Respirology       Date:  2009-12-27       Impact factor: 6.424

Review 10.  Pulmonary manifestations of endocrine and metabolic disorders.

Authors:  T Brüssel; M A Matthay; B Chernow
Journal:  Clin Chest Med       Date:  1989-12       Impact factor: 2.878

View more
  5 in total

Review 1.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 2.  Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?

Authors:  Esther de Pablo; Raquel Fernández-García; María Paloma Ballesteros; Juan José Torrado; Dolores R Serrano
Journal:  Ann Transl Med       Date:  2017-11

3.  Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema.

Authors:  Fushi Dong; Yimei Zhang; Fangzhou Chi; Qi Song; Lijuan Zhang; Yupeng Wang; Chunli Che
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis.

Authors:  Ajit A Kulkarni; Thomas H Thatcher; Hsi-Min Hsiao; Keith C Olsen; Robert Matthew Kottmann; Jason Morrissette; Terry W Wright; Richard P Phipps; Patricia J Sime
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 5.  Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management.

Authors:  René Hage; Fiorenza Gautschi; Carolin Steinack; Macé M Schuurmans
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.